Affimed Profit Margin 2014-2024 | AFMDQ
Current and historical gross margin, operating margin and net profit margin for Affimed (AFMDQ) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Affimed net profit margin as of September 30, 2024 is -7836.26%.
| Affimed Annual Profit Margins |
| Affimed Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.001B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
